S100A2 and familial pancreatic carcinoma: Further studies consist of larger sample sizes (more clinical samples and different pancreatic cancer cell lines) are required to validate the findings above and to explore the clinical application of S100A2/4/6/10/14/16 in the treatment of PDAC.